glyburide has been researched along with Spinal Cord Injuries in 14 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Spinal Cord Injuries: Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glyburide has been shown as an effective neuroprotective agent in preclinical tSCI models and in the treatment of ischaemic stroke with the additional risk of a hypoglycaemic response." | 2.90 | SCING-Spinal Cord Injury Neuroprotection with Glyburide: a pilot, open-label, multicentre, prospective evaluation of oral glyburide in patients with acute traumatic spinal cord injury in the USA. ( Boling, WW; Farhadi, HF; Mehta, A; Minnema, AJ; Schwab, J; Simard, JM, 2019) |
| "Riluzole is a pleotropic drug that blocks "persistent sodium currents" in neurons, but in SCI, its molecular mechanism of action is uncertain." | 1.38 | Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury. ( Gerzanich, V; Ivanov, A; Ivanova, S; Keledjian, K; Simard, JM; Tsymbalyuk, O, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Minnema, AJ | 1 |
| Mehta, A | 1 |
| Boling, WW | 1 |
| Schwab, J | 1 |
| Simard, JM | 9 |
| Farhadi, HF | 1 |
| Torregrossa, F | 1 |
| Sallì, M | 1 |
| Grasso, G | 1 |
| Popovich, PG | 4 |
| Tsymbalyuk, O | 6 |
| Caridi, J | 1 |
| Gullapalli, RP | 1 |
| Kilbourne, MJ | 1 |
| Gerzanich, V | 8 |
| Redondo-Castro, E | 1 |
| Hernández, J | 1 |
| Mahy, N | 1 |
| Navarro, X | 1 |
| Hosier, H | 1 |
| Peterson, D | 1 |
| Keledjian, K | 2 |
| Smith, BR | 1 |
| Ivanova, S | 4 |
| Nicholson, JD | 1 |
| Guo, Y | 1 |
| Bernstein, SL | 1 |
| Woo, SK | 3 |
| Norenberg, MD | 1 |
| Tosun, C | 1 |
| Chen, Z | 1 |
| Bryan, J | 1 |
| Landsman, D | 1 |
| Lemeshow, S | 1 |
| Gensel, JC | 1 |
| Tovar, CA | 1 |
| Ivanov, A | 3 |
| Tator, CH | 1 |
| Hashimoto, R | 1 |
| Raich, A | 1 |
| Norvell, D | 1 |
| Fehlings, MG | 1 |
| Harrop, JS | 1 |
| Guest, J | 1 |
| Aarabi, B | 1 |
| Grossman, RG | 1 |
| Kwon, MS | 1 |
| Bhatta, S | 1 |
| Geng, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Spinal Cord Injury Neuroprotection With Glyburide; Pilot Study: An Open-Label Prospective Evaluation of the Feasibility, Safety, Pharmacokinetics, and Preliminary Efficacy of Oral Glyburide (DiaBeta) in Patients With Acute Traumatic Spinal Cord Injury[NCT02524379] | Phase 1/Phase 2 | 3 participants (Actual) | Interventional | 2017-02-14 | Terminated (stopped due to Principal investigator has left the university; there were not enough participants to analyze the data.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A measure of safety of treating patients with traumatic spinal cord injury with Glyburide administered orally within a short injury-to-drug time window. (NCT02524379)
Timeframe: One year post enrollment
| Intervention | Events (Number) |
|---|---|
| Glyburide Treatment Arm | 0 |
The neurologic status of patients will be assessed using the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as assessed by International Standards for Neurological Classification of SCI (ISNCSCI) criteria. (NCT02524379)
Timeframe: One year post enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| Glyburide Treatment Arm | 2 |
A measure of feasibility of undertaking a larger phase II study among this population of patients where treatment must begin within a short injury-to-drug time window. (NCT02524379)
Timeframe: Enrollment Period (within 8 hours of tSCI)
| Intervention | Participants (Count of Participants) |
|---|---|
| Glyburide Treatment Arm | 3 |
2 reviews available for glyburide and Spinal Cord Injuries
| Article | Year |
|---|---|
Emerging Therapeutic Strategies for Traumatic Spinal Cord Injury.
Topics: Decompression, Surgical; Erythropoietin; Fibroblast Growth Factors; Glyburide; Granulocyte Colony-St | 2020 |
Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury.
Topics: Animals; Disease Models, Animal; Glyburide; Humans; Magnesium Sulfate; Minocycline; Neuroprotective | 2012 |
1 trial available for glyburide and Spinal Cord Injuries
| Article | Year |
|---|---|
SCING-Spinal Cord Injury Neuroprotection with Glyburide: a pilot, open-label, multicentre, prospective evaluation of oral glyburide in patients with acute traumatic spinal cord injury in the USA.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Female; Glyburide; Humans; Male; M | 2019 |
11 other studies available for glyburide and Spinal Cord Injuries
| Article | Year |
|---|---|
MRI evidence that glibenclamide reduces acute lesion expansion in a rat model of spinal cord injury.
Topics: Aging; Animals; Disease Models, Animal; Female; Glyburide; Hemorrhage; Magnetic Resonance Imaging; R | 2013 |
Phagocytic microglial phenotype induced by glibenclamide improves functional recovery but worsens hyperalgesia after spinal cord injury in adult rats.
Topics: Animals; Cells, Cultured; Female; Glyburide; Hyperalgesia; Locomotion; Microglia; Neuroprotective Ag | 2013 |
A Direct Comparison of Three Clinically Relevant Treatments in a Rat Model of Cervical Spinal Cord Injury.
Topics: Animals; Behavior, Animal; Cervical Cord; Disease Models, Animal; Female; Glyburide; Hypoglycemic Ag | 2015 |
SUR1-Associated Mechanisms Are Not Involved in Ischemic Optic Neuropathy 1 Day Post-Injury.
Topics: Animals; Central Nervous System; Glyburide; Hypoglycemic Agents; Immunohistochemistry; Mice, Inbred | 2016 |
Brief suppression of Abcc8 prevents autodestruction of spinal cord after trauma.
Topics: Animals; ATP-Binding Cassette Transporters; Disease Models, Animal; Gene Expression Regulation; Glyb | 2010 |
Independent evaluation of the effects of glibenclamide on reducing progressive hemorrhagic necrosis after cervical spinal cord injury.
Topics: Animals; Cervical Vertebrae; Disease Progression; Drug Evaluation, Preclinical; Female; Glyburide; H | 2012 |
When replication teaches more than the original experiment--the saga of the unknown unknown.
Topics: Animals; Disease Progression; Female; Glyburide; Hematoma, Epidural, Spinal; Spinal Cord Injuries | 2012 |
Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury.
Topics: Action Potentials; Analysis of Variance; Animals; Calcimycin; Calcium; Calcium Ionophores; Capillari | 2012 |
Spinal cord injury with unilateral versus bilateral primary hemorrhage--effects of glibenclamide.
Topics: Animals; Female; Glyburide; Hematoma, Epidural, Spinal; Rats; Rats, Long-Evans; Spinal Cord Injuries | 2012 |
The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel.
Topics: Animals; ATP-Binding Cassette Transporters; Cell Membrane; Chlorocebus aethiops; COS Cells; Diazoxid | 2013 |
Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury.
Topics: Animals; ATP-Binding Cassette Transporters; Behavior, Animal; Calcium Channels; Capillaries; Cells, | 2007 |